Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...